FDA Grants Fast Track Designation for Trethera's TRE-515
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Trethera Corporation's TRE-515, a KRAS G12C inhibitor, for the treatment of non-small cell lung cancer.
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Trethera Corporation's TRE-515, a KRAS G12C inhibitor, for the treatment of non-small cell lung cancer.